<DOC>
	<DOCNO>NCT02152449</DOCNO>
	<brief_summary>The purpose study determine whether early oral nutritional supplementation ( ONS ) amyotrophic lateral sclerosis ( ALS ) patient effective treatment rapidly progressive disease .</brief_summary>
	<brief_title>Oral Nutritional Supplementation Amyotrophic Lateral Sclerosis ( ALS ) Patients</brief_title>
	<detailed_description>Amyotrophic lateral sclerosis ( ALS ) rare neurodegenerative disease median age time diagnosis 65 year . In France , incidence range 1.5 2.5/100 000 person-year follow-up . The disease related progressive degeneration motor neuron two voluntary motor pathway . It debilitate disease , particularly term autonomy respiratory function . Its prognosis poor , constant worsen follow-up , lead death median survival 24 month diagnosis . ALS patient risk malnutrition short medium term , several factor limit stop food intake , functional disability , swallow breathe disorder . The disease also accompany 50-60 % case abnormal increase energy expenditure ( hypermetabolism ) , cause add weight loss . Previous study show malnutrition independent negative prognostic factor survival . Besides , time diagnosis , 36 % patient already lose 5 % usual weight . Such weight loss show associated 2 fold increase risk dying , adjustment know prognostic factor . Moreover , patient higher fat body mass course disease significant increase survival ; high level serum cholesterol and/or triglyceride favourable factor survival . The recommendation management ALS patient , publish French International group expert , suggest use oral nutritional supplementation food intake cover patient 's requirement . We propose Oral Nutritional Supplementation ( ONS ) use ( ) systematically ( ii ) early ( early time diagnosis ) order enable patient maintain proper nutritional status . Such intervention could delay progression disease metabolic disorder ALS solely result progression disease , implicated course outcome . This parallel randomize study aim To assess benefit early oral nutritional supplementation ( ONS ) neurological functional status evaluate slope revise ALS Functional rating Scale ( ALSFRS-R ) inclusion ( T0 ) T0+6 month newly diagnose ALS pati</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Patients ≥18 year age , diagnose ALS ( &lt; 2 month inclusion ) accord Airlie House criterion : definite , probable , probable laboratory support ; Time first symptoms diagnosis le 18 month Sporadic familial case Patient agreement follow give ALS centre duration study Patients loss least 1 point 3 item ALSFRSR rating scale loss least 2 point 2 item ALSFRSR rating scale Patients sign informed consent form Associated dementia inability understand requirement protocol . No helper ONS already begin Artificial nutrition : enteral parenteral nutrition Known hypersensitivity component ONS Absence treatment Riluzole ( RILUTEK® ) Patient guardianship curatorship Participation another research protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>